Overview

Early Infant HIV Treatment in Botswana

Status:
Active, not recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
The overall objective of this study is to determine whether very early antiretroviral treatment (ART) initiation in HIV-infected infants limits the seeding of viral reservoirs and maintains immune responses, potentially allowing future periods off ART.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Harvard School of Public Health
Harvard School of Public Health (HSPH)
Collaborators:
Brigham and Women's Hospital
Ragon Institute of MGH, MIT and Harvard
University of California, San Diego
Treatments:
Lamivudine
Lopinavir
Nevirapine
Zidovudine